Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoptosis
Azidothymidine in adult T cell leukemia/lymphoma patients results in tumor cell death
October 5th, 2006
Azidothymidine (AZT) treatment of T-cell leukemia virus I-infected cells in adult T-cell leukemia/lymphoma (ATL) patients results in tumor cell death. According to recent research published in the journal Blood, "The antiviral thymidine analog AZT is used to treat several virus-associated human cancers. However, to date, the mechanism of AZT action remains unclear and thus, reasons for treatment failure are unknown." "ATL is an aggressive malignancy of poor prognosis," explained A.K. Datta and colleagues, University of Kansas. "Here, we report that enduring AZT treatment of T-cell leukemia virus I-infected cells, in vitro and in vivo in ATL...
Source: Blood Weekly (2006-10-05)
|
